LadRx (STU:CX5) Research & Development: €0.72 Mil (TTM As of Mar. 2025)


STU:CX5 LadRx Corp STU:CX5
40 GF Score
Price €0.06
View Full Analysis

What is LadRx Research & Development?

LadRx STU:CX5 40 Research & Development is €0.72 Mil as of Mar. 2025. GuruFocus rates STU:CX5 with a GF Score™ of 40/100.

Research & Development is the aggregate amount of research and development expenses during the year. LadRx's Research & Development for the three months ended in Mar. 2025 was €0.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €0.72 Mil.

LadRx  (STU:CX5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LadRx Research & Development Related Terms

LadRx Research & Development Historical Data

* Premium members only.

The historical data trend for LadRx's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx Research & Development Chart

LadRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.00 0.00 0.26 0.74

LadRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.55 0.00 0.14 0.03
STU:CX5
40GF Score
LadRx Corp STU:CX5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LadRx Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.72 Mil mean?
LadRx (STU:CX5) has a Research & Development of €0.72 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on LadRx and its competitors.
Is LadRx's Research & Development too high?
LadRx's current Research & Development is €0.72 Mil. Overall, LadRx has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does LadRx's Research & Development compare to VRTX and REGN?
LadRx's Research & Development of €0.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LadRx and its competitors. LadRx's current Research & Development is €0.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (STU:CX5) has a current Research & Development of €0.72 Mil. The current Research & Development is €0.72 Mil. LadRx's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LadRx (STU:CX5), the current Research & Development is €0.72 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
40GF Score

Get the complete analysis for STU:CX5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price